

0583 8 APR 25 PI2:57

Pharmaceuticals for Medicine, Pharmacy and Science

April 24, 2008

Jane Axelrad
Associate Director
FDA/CDER
Office of Regulatory Policy
Documents Management
5630 Fishers Lane, Room 1061
Rockville, MD 20852



Pharmaceuticals for Medicine, Pharmacy and Science

Mary Lou Freathy, J.D.

Vice President

Quality Services, Regulatory Affairs & Compliance

3940 Quebec Avenue North Minneapolis, MN 55427 U.S.A. mifreathy@paddocklabs.com www.paddocklabs.com

Direct: 763.732.0479 800.328.5113 ext 479 Cell: 612.801.0073 Fax: 763.546.4842

DESK COPY

Re: PIND 101,370: Clobetasol Propionate Foam, 0.05% Meeting Request for Resolution of Filing Strategy

Dear Dr. Beitz:

Reference is made to Paddock Laboratories, Inc.'s (Paddock) PIND 101,370 for the above referenced drug product. Reference is also made to the telephone communication with Margo Owens, Lead Regulatory Project Manager, on April 7, 2008. In the telephone communication, Paddock was informed that the April 8, 2008 teleconference was being postponed because the Division was requesting additional information from Paddock as to why an ANDA was not being submitted for this product, even without a pending suitability petition. On April 8, 2008 Paddock submitted the additional information to the Agency. Several follow-up phone calls have been made to Ms. Owens requesting a status update and to date, Paddock's phone calls have not been returned nor has the teleconference been rescheduled.

As additional background, it should be noted that Paddock submitted a suitability petition (Docket no. 2006P-0387) on September 14, 2006, based on the Office of Generic Drugs' (OGD) May 18, 2006 recommendation, seeking the Agency's acceptance that Paddock's Clobetasol Propionate Foam, 0.05% was suitable for submission as an ANDA. Several phone calls were made to OGD requesting a status update; these status calls were not returned. Paddock amended the petition on February 5, 2008 for clarification purposes and to provide the Agency with appropriate examples.

Dr. Julie Beitz Office of New Drugs April 24, 2008 Page 2

At this time, Paddock is requesting a meeting with the Agency to determine the appropriate filing strategy for the above referenced drug product. Paddock has already missed a first to file opportunity as an ANDA and development of Paddock's product is nearing completion. Paddock believes that enough time has passed and that it is critical that Paddock receive guidance from the Agency as to what application type is appropriate for this product.

This correspondence is also being sent to Jane Axelrad, Elizabeth Dickinson, John K. Jenkins, Helen Winkle and Gary Buehler as a desk copy in order to help facilitate the filing determination.

Should you have any questions or comments regarding this correspondence, please contact me at (763) 732-0479 (telephone) or (763) 546-4842 (fax). I look forward to the Agency's response.

Sincerely,

PADDOCK LABORATORIES, INC.

Mary Lou Freathy

Vice President, Quality, Regulatory Affairs, and Compliance

Desk Copy: Jane Axelrad, Director, Office of Regulatory Policy

Elizabeth Dickinson, Attorney, Office of Chief Counsel

John K. Jenkins, Director, Office of New Drugs


Helen Winkle, Director, Office of Pharmaceutical Science

Gary Buehler, Director, Office of Generic Drugs

949

UPS Worldwide Express" **UPS Next Day Air**®

UPS 2nd Day Air[®]



a € € 6

2

ion") and/or the Conver

International Shipping Notice — Carriage hereunder, may be subject to the rules relating to liability and other terms and/or conditions established by the Convention for the Unification of Certain Rules Relating to International Carriage by Air (the "Warsaw Conve

Contact for the International Carinaes of Goods tor Road (the "CMR Convention"). These commodities, technology or software were exported from the U.S. in arcudance with the Front Administration